DexCom, Inc. DXCM
- Market cap
- $33.0B
- P/E
- 33.4×
Follow DXCM
DexCom, Inc. (DXCM) EV/Sales
As of 25 September 2026, DexCom, Inc. (DXCM) trades at a EV/Sales of 6.5×. Over the past ten years it has ranged from 4.3× (November 2025) to 26.8× (November 2021); the current reading is higher than 11% of that period. That is above the Medical Devices industry median of 2.4× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Annual
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 5.4× | (25.63%) |
| FY2024 | 7.3× | (44.23%) |
| FY2023 | 13.1× | (13.89%) |
| FY2022 | 15.2× | (27.40%) |
| FY2021 | 20.9× | 18.99% |
| FY2020 | 17.6× | 33.27% |
| FY2019 | 13.2× | 33.50% |
| FY2018 | 9.9× | 48.33% |
| FY2017 | 6.7× | (19.56%) |
| FY2016 | 8.3× | (48.19%) |
Quarterly
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 5.1× | 5.44% |
| Mar 2026 | 4.8× | (11.38%) |
| Dec 2025 | 5.4× | 0.46% |
| Sep 2025 | 5.4× | (28.95%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SNN Smith & Nephew SNATS, Inc. compare | 1.4× |
| PHG Koninklijke Philips N.V. compare | 1.4× |
| GEHC GE HealthCare Technologies Inc. compare | 1.9× |
| ZBH Zimmer Biomet Holdings, Inc. compare | 2.9× |
| STE STERIS plc compare | 3.6× |
| BSX Boston Scientific Corporation compare | 3.7× |
| DXCM DexCom, Inc. | 6.5× |
| EW Edwards Lifesciences Corporation compare | 7.1× |
| PEN Penumbra, Inc. compare | 7.9× |
| Medical Devices industry median | 2.4× |
| Healthcare sector median | 3.6× |
| Market median | 2.2× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on DXCM
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement